Novartis vs Pharmaron: CDMO Comparison
How does Novartis compare to Pharmaron?
As of Nov 2026, Novartis: 17 FDA inspections (including 9 NAI, 8 VAI and 0 OAI), 51 EMA/MHRA GMP certificates. Signal Score 85.4. Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Novartis and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (17 vs 5) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Novartis holds 50 active EMA GMP certificates; Pharmaron does not appear in EudraGMDP.
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
Across the cross-modality scorecard, Pharmaron carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Novartis vs Pharmaron
How does Novartis compare to Pharmaron?
On CDMO Signal's composite Signal Score, Novartis is 85/100 and Pharmaron is 87/100; Novartis has 17 FDA inspections on record vs 5 for Pharmaron; European coverage is 51 active EMA+MHRA certificates for Novartis vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Novartis or Pharmaron?
Both Novartis and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Novartis has 17 FDA inspections on record; Pharmaron has 5.
How do Novartis and Pharmaron compare on European GMP coverage?
Novartis holds 50 active EMA GMP certificates and 1 MHRA / UK certificate. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Novartis or Pharmaron?
Novartis is matched to 137 ClinicalTrials.gov records as a manufacturing partner; Pharmaron is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
Novartis carries a Signal Score of 85/100 and Pharmaron carries 87/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →